Amanda Hays

Dr. Amanda Hays

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2024 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
AHAmanda Hays
Amanda Hays
MWMark Wissel
Mark Wissel
KCKelly Colletti
Kelly Colletti
RSRussell Soon
Russell Soon
MAMitra Azadeh
Mitra Azadeh
OJOskar Johansson
Oskar Johansson
: The emerging use of qPCR and dPCR in regulated bioanalysis and absence of regulatory guidance on assay validations for these platforms has resulted in discussions on lack of harmonization on assay design and appropriate acceptance criteria for these assays. Both qPCR and dPCR are extensively used to answer bioanalytical questions for novel modalities such as cell and gene therapies. Following cross-industry conversations on the lack of information and guidelines for these assays, an American Association of Pharmaceutical Scientists working group was formed to address these gaps by bringing together 37 industry experts from 24 organizations to discuss best practices to gain a better understanding in the industry and facilitate filings to health authorities. Herein, this team provides considerations on assay design, development, and validation testing for PCR assays that are used in cell and gene therapies including (1) biodistribution; (2) transgene expression; (3) viral shedding; (4) and persistence or cellular kinetics of cell therapies. Graphical Abstract

22 February 2022 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
AHAmanda Hays
Amanda Hays
RIRafiq Islam
Rafiq Islam
KMKatie Matys
Katie Matys
DWDave Williams
Dave Williams

Verified
Journal Article
Open access
PDF file
AHAmanda Hays
Amanda Hays
JDJennifer Durham
Jennifer Durham
BGBryan Gullick
Bryan Gullick
NRNathan Rudemiller
Nathan Rudemiller
TSThomas Schneider
Thomas Schneider
A vast evolution of drug modalities has occurred over the last several decades. Novel modalities such as cell and gene therapies have proven to be efficacious for numerous clinical indications–primarily in rare disease and immune oncology. Because of this success, drug developers are heavily investing in these novel modalities. Given the complexity of these therapeutics, a variety of bioanalytical techniques are employed to fully characterize the pharmacokinetics of these therapies in clinical studies. Industry trends indicate that quantitative PCR (qPCR) and multiparameter flow cytometry are both valuable in determining the pharmacokinetics, i.e. cellular kinetics, of cell therapies. This manuscript will evaluate the pros and cons of both techniques and highlight regulatory guidance on assays for measuring cellular kinetics. Moreover, common considerations when developing these assays will be addressed.

5 May 2022 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
AHAmanda Hays
Amanda Hays
LALakshmi Amaravadi
Lakshmi Amaravadi
CFCarmen Fernandez-Metzler
Carmen Fernandez-Metzler
LKLindsay King
Lindsay King
JMJoel Mathews
Joel Mathews
JZJianing Zeng
Jianing Zeng

18 September 2025 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
JPJason Pennucci
Jason Pennucci
AHAmanda Hays
Amanda Hays
WAWendy Adamowicz
Wendy Adamowicz
MAMitra Azadeh
Mitra Azadeh
MBMohamed Benhammadi
Mohamed Benhammadi
SZSusan Zondlo
Susan Zondlo
Lipid nanoparticle-messenger RNA (LNP-mRNA) drug products are a growing class of drug modalities. The unique composition of these drug products requires multiple measurements to account for the different components of these drug modalities. Pharmacokinetic (PK) measurements include measurement of the encapsulated mRNA and components of the LNP in circulation to understand the effectiveness of the therapeutic mRNA. The PK measurements can utilize many different platforms including PCR. Current regulatory guidance documents for bioanalytical method validation are specific to ligand binding and chromatographic assay methods and difficult to interpret for use with molecular workflows. The purpose of this paper is to provide information on considerations for validation of regulated reverse transcription quantitative PCR (RT-qPCR) assays that are used to support the pharmacokinetic analysis of LNP-mRNA drug products. Graphical Abstract

2 January 2026 in Bioanalysis
Verified
Journal Article
Closed access
CFCarmen Fernández-Metzler
Carmen Fernández-Metzler
KQKaren J. Quadrini
Karen J. Quadrini
LALakshmi Amaravadi
Lakshmi Amaravadi
SCStephanie Cape
Stephanie Cape
JGJennifer Green
Jennifer Green
MHMohamed Hassanein
Mohamed Hassanein
Pharmacodynamic (PD) biomarkers provide crucial insights into a drug's mechanism of action (MoA) and efficacy by measuring its effects on biological targets within an organism. PD biomarkers can be proximal (e.g. receptor occupancy, enzyme inhibition) or distal (e.g. downstream pathway modulation) to the biological target. In drug development, PD biomarkers are essential for monitoring patient response, assessing therapeutic efficacy, optimizing dosage strategies, and streamlining the drug development process by informing go/no-go decisions. In personalized medicine, PD biomarkers enable tailored treatments based on individual responses, enhancing both effectiveness and safety. Sound bioanalytical strategies and rigorous assay validation practices are key for successful integration of PD biomarkers into clinical trials. This paper outlines the bioanalytical and assay considerations for developing and validating informative PD biomarker assays and their use in drug development.